Autoimmune hepatitis medical therapy

Jump to navigation Jump to search


Autoimmune hepatitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating autoimmune hepatitis differential diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Diagnostic of choice

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune hepatitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune hepatitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune hepatitis medical therapy

CDC on Autoimmune hepatitis medical therapy

Autoimmune hepatitis medical therapy in the news

Blogs on Autoimmune hepatitis medical therapy

Directions to Hospitals Treating Autoimmune hepatitis

Risk calculators and risk factors for Autoimmune hepatitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Acute Pharmacotherapies

  • Despite our clear understanding of the pathogenesis and pathophysiology of AH, approximately 80 % of patients will have a good initial response to corticosteroids, with a ten-year survival rate approaching 90%.
  • The decision to treat patients with only mild disease is often based on symptoms.
  • Asymptomatic patients with mild inflammation on Bx can be observed with careful monitoring of histology.
  • The goal of therapy is generally normalization of both transaminases and histology, and in general, most patients who are going to respond do so by 6 months.
  • Unfortunately, the results with alternate-day or pulsed steroid regimens have been disappointing and daily regimens are preferred.
  • Azathioprine can be used as a steroid-sparing agent.
  • Additionally, some authors recommend using lower prednisone doses with the goal of partial suppression of disease, as opposed to higher doses of steroids with the goal being remission.
  • For the 10 – 20% of patients who develop progressive disease despite steroids and/or azathioprine, cyclosporine and tacrolimus have recently been shown to induce remission.
  • There are no firm guidelines concerning the tapering or discontinuation of therapy.

Recommendations for the treatment of Autoimmune Hepatitis (DO NOT EDIT)

  1. Immunosuppressive treatment based on serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum gamma-globulin levels, and histological features
    1. Prednisone or prednisolone with azathioprine (adults)
    2. Prednisone with azathioprine or 6-mercaptopurine (children)
    3. Prednisone or prednisolone alone
  2. Monitoring for bone disease
  3. Adjunctive therapies for bone disease (weight bearing exercise program, vitamin D and calcium supplementation, bisphosphonates)
  4. Pretreatment vaccination against hepatitis A virus (HAV) and hepatitis B virus (HBV)
  5. Management of treatment side effects and risks, including during pregnancy
  6. Alternative drug therapies for suboptimal response (cyclosporine, tacrolimus, or mycophenolate mofetil)
  7. Hepatic ultrasonography to detect hepatocellular carcinoma (HCC)
  8. Liver transplantation, management of recurrent disease after transplant with drug therapy and/or retransplantation in certain patients

References